Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NMRAthis companyNeumora Therapeutics, Inc. Common Stock	$0.53	-1.23×	2.82×	0×	-0.47×	121.4%	0.0%	0.0%	0.0%	-228.1%	-151.8%	-70.6%	0×	0.78×	-74.92×	5.87×	0.0%	2	-18.15	2	C+
ALMSAlumis Inc.	$6.39	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
FDMT4D Molecular Therapeutics, Inc.	$12.43	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
FULCFulcrum Therapeutics, Inc.	$3.70	-9.58×	2.05×	0×	-7.15×	-17.6%	0.0%	0.0%	0.0%	-21.5%	-23.8%	-8.4%	0.02×	2.6×	0×	27.4×	0.0%	2	10.2	3	B
LXRXLexicon Pharmaceuticals, Inc.	$1.87	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
OMEROmeros Corporation	$17.52	-326×	-9×	0×	-720.85×	-117.8%	0.0%	0.0%	0.0%	2.8%	-45.3%	-10.6%	-1.97×	-125.26×	0×	2.76×	0.0%	6	0.2	2	C+
Peer median	—	-8.21×	2.05×	5.1×	-10.76×	-117.8%	85.5%	-98.2%	-101.1%	-27.7%	-30.2%	-10.6%	0.04×	0.21×	0×	4.88×	0.0%	2	0.2	2	—